Related references
Note: Only part of the references are listed.The prognostic and predictive value of serum CA19.9 in pancreatic cancer
J. L. Humphris et al.
ANNALS OF ONCOLOGY (2012)
Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades
Jordan M. Winter et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer
Timothy R. Donahue et al.
CLINICAL CANCER RESEARCH (2012)
Urine Metabolic Signature of Pancreatic Ductal Adenocarcinoma by 1H Nuclear Magnetic Resonance: Identification, Mapping, and Evolution
Claudia Napoli et al.
JOURNAL OF PROTEOME RESEARCH (2012)
K-ras Mutations in the Plasma Correspond to Computed Tomographic Findings in Patients With Pancreatic Cancer
Jan Daebritz et al.
PANCREAS (2012)
Correction: A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
Jordan M. Winter et al.
PLoS One (2012)
Pancreatic Cancer Surgery in the New Millennium Better Prediction of Outcome
Werner Hartwig et al.
ANNALS OF SURGERY (2011)
Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component Analysis
Dong OuYang et al.
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY (2011)
A Phase 2 Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma
Harvey J. Mamon et al.
CANCER (2011)
Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics
Oliver F. Bathe et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Serum Biomarker Panels for the Detection of Pancreatic Cancer
Randall E. Brand et al.
CLINICAL CANCER RESEARCH (2011)
The Clinical Utility and Limitations of Serum Carbohydrate Antigen (CA19-9) as a Diagnostic Tool for Pancreatic Cancer and Cholangiocarcinoma
Sundeep Singh et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression
Christopher H. Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions
Maeve A. Lowery et al.
ONCOLOGIST (2011)
Tissue and Serum microRNAs in the KrasG12D Transgenic Animal Model and in Patients with Pancreatic Cancer
Joseph J. LaConti et al.
PLOS ONE (2011)
Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
Naru Kondo et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy
Nazik Hammad et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2010)
Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray
David L. Morse et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2
Yefei Rong et al.
BMC GASTROENTEROLOGY (2010)
Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis
A. Xue et al.
BRITISH JOURNAL OF CANCER (2010)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma
Jeran K. Stratford et al.
PLOS MEDICINE (2010)
Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation Report of Toxicity and Evaluation of Circulating K-ras cis a Potential Biornarker of Response to Therapy
Christine C. Olsen et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions
Daniele Marrelli et al.
AMERICAN JOURNAL OF SURGERY (2009)
MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease
Jin Wang et al.
CANCER PREVENTION RESEARCH (2009)
The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
Christina L. Costantino et al.
CANCER RESEARCH (2009)
Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis
Jinghui Guo et al.
CANCER SCIENCE (2009)
The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray
Tasneem H. Patwa et al.
ELECTROPHORESIS (2009)
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status
Rodrigo Jover et al.
EUROPEAN JOURNAL OF CANCER (2009)
Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer
Scott A. Waldman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?
O. Turrini et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Joshua G. Barton et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Sian Jones et al.
SCIENCE (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
A Compendium of Potential Biomarkers of Pancreatic Cancer
H. C. Harsha et al.
PLOS MEDICINE (2009)
CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
M. Bedi et al.
INDIAN JOURNAL OF GASTROENTEROLOGY (2009)
The Impact of Resection Margin Status and Postoperative CA19-9 Levels on Survival and Patterns of Recurrence After Postoperative High-Dose Radiotherapy With 5-FU-Based Concurrent Chemotherapy for Resectable Pancreatic Cancer
Timothy J. Kinsella et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma
Shishir K. Maithel et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer
Sandra Perez-Torras et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection
Chanjuan Shi et al.
CANCER BIOLOGY & THERAPY (2008)
Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy
John C. Cheville et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
Adam C. Berger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
Kerby Shedden et al.
NATURE MEDICINE (2008)
Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
Derrick Wong et al.
PANCREAS (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Targeting Fanconi anemia/BRCA2 pathway defects in cancer: The significance of preclinical pharmacogenornic models
Eike Gallmeier et al.
CLINICAL CANCER RESEARCH (2007)
Improving resectability of hepatic colorectal metastases: Expert consensus statement
Eddie K. Abdalla et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
Cristina R. Ferrone et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma
TL Hwang et al.
PROTEOMICS (2006)
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
NR Maisey et al.
BRITISH JOURNAL OF CANCER (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer
I Alldinger et al.
PANCREATOLOGY (2005)
Comprehensive proteomic analysis of human pancreatic juice
M Gronborg et al.
JOURNAL OF PROTEOME RESEARCH (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis
E Missiaglia et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
C Ziske et al.
BRITISH JOURNAL OF CANCER (2003)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
